1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Zhejiang Yatai Pharmaceutical Co., Ltd.

Zhejiang Yatai Pharmaceutical Co., Ltd.

002370.SZ
Zhejiang Yatai Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
5.56
CNY
+0.07
- -
4.15BMarket Cap
Zhejiang Yatai Pharmaceutical Co., Ltd.
002370.SZ
(Shenzhen Stock Exchange)

Recent

price

5.56

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.14
1.01
0.8
0.86
0.93
1.13
1.73
1.69
2.1
1.32
0.94
0.59
0.7
0.71
0.59
0.44
0.45
Revenue per Share
0.11
0.11
-0.06
0.01
0.1
0.14
0.22
0.26
0.28
-3.58
0.05
-0.43
-0.25
-0.02
0.05
0.13
0.18
Basic EPS, GAAP
-0.19
0.03
-0.1
0.02
-0.05
0.16
-0.26
-0.29
-1.1
-0.65
-0.04
-0.04
-0.02
0.01
0.02
0.03
-0.01
Free Cash Flow per Basic Share
0.01
0.05
0.05
- -
0.01
0.06
0.1
0.05
0.11
0.08
0.03
0.03
0.03
0.03
0.02
0.05
0.05
Dividend per Share
0.7
0.89
0.83
0.91
0.9
0.96
1.22
1.69
1.85
-1.75
-1.67
-2.15
-2.4
-2.04
-1.55
-1.28
-1.26
Book Value per Share
1.82
1.73
1.68
1.84
1.7
0.08
3.2
2.84
2.79
0.99
1
0.59
0.42
0.86
1.32
1.45
1.44
Tangible Book Value per Share
382
417
396
365
406
411
440
537
539
537
545
531
531
594
685
741
743
Basic Weighted Avg Shares
435
420
316
314
376
463
762
907
1,132
709
515
315
373
421
405
323
335
Sales/Revenue/Turnover
11.47
10.13
-9.62
1.46
12.4
13.57
17.82
17.99
17.5
-17
-11.38
-39.02
-2.45
-6.19
-0.51
-3.79
-5.52
Operating Margin (%)
17
19
20
24
25
29
39
38
44
53
49
44
42
39
37
32
- -
Depreciation Expense
42
44
-26
5
41
55
97
140
151
-1,921
27
-228
-133
-12
34
96
134
Net Income, GAAP
12.93
13.18
- -
5.51
16.16
14.39
10.5
14.11
12.62
- -
3.95
- -
- -
- -
0.71
0.13
0.6
Effective Tax Rate (%)
9.66
10.42
-8.14
1.75
10.8
11.98
12.7
15.38
13.33
-270.79
5.3
-72.44
-35.53
-2.82
8.45
29.8
39.94
Profit Margin (%)
465
468
390
400
394
99
947
907
810
1,309
982
782
782
793
539
746
737
Working Capital
- -
- -
- -
- -
- -
513
- -
100
165
982
933
863
900
639
- -
- -
- -
LT Debt
720
745
704
710
747
793
2,166
2,278
2,376
633
660
433
301
581
972
1,120
1,129
Total Equity
7.63
4.67
- -
0.59
5.26
4.63
6.5
6.14
6.91
- -
-3.34
- -
- -
- -
-0.16
-1.01
-1.56
Return on Invested Capital (%)
13.85
12.15
- -
1.74
11.13
7.55
13.68
17.45
13.95
- -
86.7
- -
- -
- -
-10.34
-15.66
-24.16
Return on Capital (%)
18.14
13.75
-7.35
1.65
11.6
14.58
20.81
19.33
15.85
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
332
300
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
729
740
746
Market Capitalization
1,866
2,475
2,824

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
955
1,005
837
Cash, Cash Equivalents & STI
744
777
625
Accounts Receivable, Net
95
89
97
Inventories
70
80
69
Total Current Liabilities
416
431
100
Payables & Accruals
- -
- -
- -
ST Debt
332
300
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.41%
22.11%
15.23%
Free Cash Flow
-16.1%
-14.97%
63.78%
Net Income, GAAP
-262.4%
-255.38%
181.27%
Sales/Revenue/Turnover
1.21%
-6.32%
-20.25%
Total Cash Common Dividend
28.03%
39.58%
214%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
113
109
85
98
405
2025
65
88
95
- -
323
2026
60
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.05
2025
-0.01
- -
- -
- -
0.13
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.02
2025
- -
- -
- -
- -
0.05
2026
- -
- -
- -
- -
- -
Similar Companies
1CM Inc. (MILFF)
Hikma Pharmaceuticals PLC (HKMPF)
Gold River Productions, Inc. (GRPS)
DV Biomed Co., Ltd. (6539.TWO)
TTY Biopharm Company Limited (4105.TWO)
Huons Global Co., Ltd. (084110.KQ)
Business
Zhejiang Yatai Pharmaceutical Co., Ltd. (002370.SZ) researches, develops, manufactures, sells, and exports pharmaceutical products primarily in China and internationally; the company specializes in chemical preparations, active pharmaceutical ingredients, and generic drugs across antibiotic and non-antibiotic categories. Main products include antibiotic offerings such as amoxicillin clavulanate potassium dispersible tablets, azithromycin dispersible tablets, roxithromycin capsules, injectable cefazoxime sodium, and injectable cefumizole sodium; non-antibiotic drugs encompass digestive system medications like injectable pantoprazole sodium, injectable omeprazole sodium, omeprazole enteric capsules, and lansoprazole enteric capsules, as well as antiviral agents including ribavirin injections, aloxivir injections, and aciclovir injections, alongside cardiovascular drugs and antipyretic analgesics; the company also produces tablets, capsules, patches, powder injections, troches, chemical agents, raw materials, and diagnostic reagents, while providing pharmaceutical research and development outsourcing services. Founded in 1989 and headquartered in Shaoxing, Zhejiang Province, China, the company--formerly Zhejiang Asia Pacific Pharmaceutical Factory--completed shareholding system reform in 2001 and listed on the Shenzhen Stock Exchange in 2010; it operates as a national high-tech enterprise targeting domestic hospital networks, retail chains, clinics, and export markets. Recent developments include a March 2025 agreement to transfer 100% equity in subsidiary Shaoxing Xingya Pharmaceutical Co., Ltd. to Zhejiang Zhongqingda Construction Industry Co., Ltd. for CNY 175 million including debt assumption, and an October 2025 share subscription agreement with Zhejiang Xinghao Holding Partnership Enterprise (Limited Partnership) for approximately CNY 700 million via private placement of 136.99 million shares at CNY 5.11 each to fund R&D projects, both pending regulatory approvals.